HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS

Clinical trials for HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS explained in plain language.

Never miss a new study

Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS trials appear

Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New hope for hard-to-treat lymphoma: triple-drug combo enters early trials

Disease control Not yet recruiting

This early-phase trial is testing whether a combination of three drugs (golcadomide, poseltinib, and rituximab) can shrink tumors in people with large B-cell lymphoma that has come back or not responded to prior treatment. The study will enroll 20 adults and measure how many pati…

Matched conditions: HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS

Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control

Last updated Jun 17, 2026 04:24 UTC

HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS

Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS trials appear

New hope for hard-to-treat lymphoma: triple-drug combo enters early trials